Kerem Erdoğan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Kerem Erdoğan has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Gaye Öztürk
Hacettepe Üniversitesi
1 shared publication - Turgut Emrah Bozkurt
Hacettepe University
1 shared publication - Tülay Özge Alpaslan
Hacettepe Üniversitesi
1 shared publication
Latest Publications
- 30 October 2026
- Published by FABAD Farmasotik Bilimler Ankara Dernegi in Fabad Journal of Pharmaceutical Sciences
- Vol. 51 (3) , 1561-1578
The Endocannabinoid System in Allergic Airway Diseases: Mechanisms and Therapeutic Potential
Allergic airway diseases, including allergic asthma and rhinitis, are characterised by airway inflammation and altered responses to inhaled allergens. The endocannabinoid system (ECS) significantly contributes to the regulation of airway tone and immune system activity. Experimental studies indicate that cannabinoid receptor ligands and inhibitors of endocannabinoid metabolism can modify airway hyperreactivity, inflammatory cell recruitment, and allergic inflammation. However, these effects are not uniform. CB1 and CB2 receptor signalling may produce different outcomes depending on the ligand, responding cell population, tissue, and experimental model. Endocannabinoid-related lipids may likewise exert protective or pro-inflammatory effects through different pathways. Evidence for therapeutic targeting of the ECS is more extensive in allergic asthma, where improvements in airway function or inflammation have been reported. In allergic rhinitis, pharmacological evidence remains limited, and the available clinical findings are insufficient to draw definitive conclusions. The established data suggests the ECS as a potential target in allergic airway diseases while underscoring the need to clarify receptor-dependent and receptor-independent mechanisms mediating their effects and establish efficacy and safety in well-characterized human populations. This review focuses on the role of the ECS in allergic airway diseases and evaluates its potential as a therapeutic target.
- 30 October 2026
- Published by FABAD Farmasotik Bilimler Ankara Dernegi in Fabad Journal of Pharmaceutical Sciences
- Vol. 51 (3) , 1561-1578
The Endocannabinoid System in Allergic Airway Diseases: Mechanisms and Therapeutic Potential
Allergic airway diseases, including allergic asthma and rhinitis, are characterised by airway inflammation and altered responses to inhaled allergens. The endocannabinoid system (ECS) significantly contributes to the regulation of airway tone and immune system activity. Experimental studies indicate that cannabinoid receptor ligands and inhibitors of endocannabinoid metabolism can modify airway hyperreactivity, inflammatory cell recruitment, and allergic inflammation. However, these effects are not uniform. CB1 and CB2 receptor signalling may produce different outcomes depending on the ligand, responding cell population, tissue, and experimental model. Endocannabinoid-related lipids may likewise exert protective or pro-inflammatory effects through different pathways. Evidence for therapeutic targeting of the ECS is more extensive in allergic asthma, where improvements in airway function or inflammation have been reported. In allergic rhinitis, pharmacological evidence remains limited, and the available clinical findings are insufficient to draw definitive conclusions. The established data suggests the ECS as a potential target in allergic airway diseases while underscoring the need to clarify receptor-dependent and receptor-independent mechanisms mediating their effects and establish efficacy and safety in well-characterized human populations. This review focuses on the role of the ECS in allergic airway diseases and evaluates its potential as a therapeutic target.